A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.

NCT00233870 · clinicaltrials.gov ↗

COMPLETED

Status

405

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: Agalsidase beta (recombinant form)

Sponsor

Genzyme, a Sanofi Company